Evaxion A/S (NASDAQ:EVAX) Lowered to “Hold” Rating by Wall Street Zen

Evaxion A/S (NASDAQ:EVAX) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday.

Several other research firms also recently commented on EVAX. Lake Street Capital cut their target price on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a research note on Monday, March 9th. JonesTrading assumed coverage on Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Maxim Group started coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Evaxion A/S has an average rating of “Moderate Buy” and an average price target of $11.00.

Evaxion A/S Trading Down 2.3%

NASDAQ EVAX opened at $3.91 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. The firm’s 50 day moving average price is $3.68 and its two-hundred day moving average price is $4.67. The stock has a market cap of $32.61 million, a price-to-earnings ratio of -2.96 and a beta of 0.28. Evaxion A/S has a twelve month low of $1.20 and a twelve month high of $12.15.

Institutional Investors Weigh In On Evaxion A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of EVAX. Northwestern Mutual Wealth Management Co. bought a new position in Evaxion A/S in the 4th quarter valued at $38,000. Wesbanco Bank Inc. bought a new stake in shares of Evaxion A/S during the fourth quarter worth $48,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Evaxion A/S in the fourth quarter valued at $72,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.